Pin your most used calculators here by clicking the star in the dropdown.
NCCN-IPI (Lymphoma)
Clinical Context & Background
The NCCN-IPI improves upon the original IPI by refining the scoring for Age and LDH, and emphasizing the importance of specific extranodal sites (Bone Marrow, CNS, Liver/GI, Lung). It better discriminates between low and high risk groups in the Rituximab era.
Formula Logic
Sum of points for Age, LDH, Extranodal Sites, Ann Arbor Stage, and ECOG.Reference Data
| Risk Group | Score | 5-Year Overall Survival |
|---|---|---|
| Low Risk | 0 - 1 | 96% |
| Low-Intermediate | 2 - 3 | 82% |
| High-Intermediate | 4 - 5 | 64% |
| High Risk | ≥ 6 | 33% |
Evidence-based oncology decision support. Verify with clinical guidelines.